Bold Start: Tissue-free ctDNA can predict relapse in high-risk early TNBC earlier and more broadly than traditional tumor-informed methods—and this changes the game for monitoring. But here’s where it gets controversial: does earlier molecular detection translate into better patient outcomes without driving overtreatment? This SABCS 2025 report on the c-TRAK TN Trial offers a thorough look at tissue-free, methylation-based ctDNA detection and how it stacks up against tumor-informed ddPCR, with clear implications for practice and further study.
Background and Rationale
Detecting circulating tumor DNA after curative-intent therapy serves as a powerful predictor of recurrence in early breast cancer. Until now, most evidence has come from tumor-informed assays that require sequencing of the primary tumor to design personalized mutation panels. While these approaches are highly sensitive, they depend on archived tissue, can have long sequencing turnaround times, and entail logistical complexity.
Tissue-free ctDNA assays avoid the need for prior tumor sequencing, offering a potential alternative if they can demonstrate equal or superior accuracy and prognostic value. This analysis aimed to determine the prognostic significance of tissue-free ctDNA detection in early TNBC and to directly compare its performance with tumor-informed digital droplet PCR (ddPCR) within the same patient population.
c-TRAK TN Trial’s Study Design
The analysis used plasma samples from c-TRAK TN, the first prospective ctDNA surveillance study in early-stage TNBC. In c-TRAK TN, patients at moderate to high relapse risk underwent quarterly ctDNA testing after completing standard therapy, using ddPCR to track tumor-specific mutations.
Archived plasma samples from this cohort were retrospectively assessed with a tissue-free, methylation-based ctDNA assay, enabling a head-to-head comparison within the same well-characterized group.
Tissue-Free ctDNA Assay Methodology
The tissue-free assay leverages differences in DNA methylation between cancer and non-cancer DNA. Cell-free DNA is extracted from 2–4 mL of plasma, partitioned by methylation status, and enriched with a targeted panel covering about 20,000 differentially methylated regions (DMRs), including roughly 3,000 breast-specific regions. The tumor methylation fraction is reported for ctDNA-positive samples and correlates with tumor purity.
Crucially, this approach eliminates the need for tumor sequencing while preserving biological specificity for breast cancer–derived ctDNA.
Patient Cohort and Follow-Up
A total of 1,026 plasma samples from 159 patients were analyzed with the tissue-free assay, with a median of 10 samples per patient. Quality control pass rates were high (98.6%). Median follow-up from the first surveillance blood draw was 33.9 months.
The cohort reflected high-risk early TNBC, with most tumors being high-grade and the majority of patients having received neoadjuvant and/or adjuvant chemotherapy.
ctDNA Detection and Risk of Recurrence
Detection of ctDNA at any point during serial surveillance strongly correlated with recurrence risk. Patients with detectable ctDNA had a median recurrence-free survival (RFS) of 14.9 months, while those without ctDNA detection did not reach median RFS.
This association was robust, with a time-dependent hazard ratio of 28.7 (p < 0.001), underscoring the strong prognostic value of ctDNA detection in this high-risk group.
Tissue-Free Assay Versus Tumor-Informed ddPCR
Direct comparison with ddPCR showed the tissue-free assay achieving 95.4% concordance at the sample level. Among 42 patients with ctDNA detected by either method at any time point, roughly two-thirds were detected by both assays simultaneously. Importantly, about one-third were detected earlier by the tissue-free assay, while no patient was detected earlier by ddPCR.
At 12 months, estimated ctDNA detection was 29.0% for the tissue-free assay versus 23.7% for ddPCR, indicating the tissue-free approach identified ctDNA in more patients.
Clinical Lead Time to Relapse
The tissue-free assay also suggested a longer interval between first ctDNA detection and actual relapse. Median time from ctDNA detection to recurrence was 7.8 months for the tissue-free assay vs. 5.8 months for ddPCR. Although this difference did not reach conventional statistical significance (HR 0.63, p = 0.07), the numerical advantage hints at earlier molecular detection without relying on tumor sequencing.
Conclusions and Implications
This SABCS 2025 presentation shows that tissue-free ctDNA detection can anticipate relapse with high accuracy in high-risk early TNBC. Compared with tumor-informed ddPCR, the tissue-free assay detected ctDNA more often and earlier, while maintaining strong prognostic discrimination.
Ongoing comparisons with whole-exome sequencing–based tumor-informed assays will help clarify relative performance. While these findings establish solid analytical validity and prognostic value, prospective interventional studies are needed to determine whether tissue-free ctDNA surveillance can guide treatment decisions and improve outcomes.
For more information, click here: https://sabcs.org/
